株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

BCL-2(B細胞リンパ腫2)阻害剤の世界市場:2019年~2023年

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 905966
出版日 ページ情報 英文 111 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
BCL-2(B細胞リンパ腫2)阻害剤の世界市場:2019年~2023年 Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2019-2023
出版日: 2019年08月02日 ページ情報: 英文 111 Pages
概要

世界のBCL-2(B細胞リンパ腫2)阻害剤市場は、高齢者人口の増加、血液悪性腫瘍に関する意識の高まり、BCL-2阻害剤の高い標的親和性と特異性などの市場成長因子により、予測期間中に約39%のCAGRで拡大する見込みです。ただし、代替品の入手可能性、BCL-2阻害剤の副作用、および薬剤耐性などが、予測期間中のBCL-2阻害剤業界の成長を妨げる可能性があります。

当レポートでは、世界のBCL-2(B細胞リンパ腫2)阻害剤市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代用品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • 併用療法
  • 単剤療法
  • 市場機会:製品別

第7章 顧客情勢

第8章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • 患者支援プログラムの増加
  • 戦略的提携
  • 新規製剤の開発

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

目次
Product Code: IRTNTR31810

About this market

BCL-2 inhibitors are used as a targeted therapy to treat cancer by blocking the BCL-2 protein. Technavio's BCL-2 inhibitors market analysis considers sales from the combination therapy and monotherapy segments. Our analysis also considers the sales of BCL-2 inhibitors in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as label expansion of venetoclax from monotherapy to combination therapy and high efficacy and tolerability of combination therapy compared with monotherapy will significantly help the market segment in maintaining its leading position. Also, our global BCL-2 inhibitors report has observed market growth factors such as rise in geriatric population, growing awareness about hematological malignancies, and high target affinity and specificity of BCL-2 inhibitors. However, the availability of substitutes, adverse effects of BCL-2 inhibitors, and drug resistance may hamper the growth of the BCL-2 inhibitors industry over the forecast period.

Overview

Growing awareness about hematological malignancies

Most of the times, symptoms of hematological malignancies are mild or not apparent. This may hamper the market growth as the patient may not know how to identify symptoms and opt to visit a specialist. To combat this challenge, many organizations and market vendors have been organizing awareness programs to educate patients about indication symptoms and available diagnostic methods and treatment options. These awareness programs also conduct cancer screening. As a result, appropriate diagnosis and treatment will take place. This will increase sales of BCL-2 inhibitors, which will lead to the expansion of the BCL-2 inhibitors market at a CAGR of almost 39% during 2019-2023.

Development of novel formulations

The only approved therapy available in the market to treat hematological malignancies is venetoclax, which has limited anti-BCL activity. Therefore, vendors have started formulating novel drugs that can be administered in combination with other therapies. These novel drugs are formulated to overcome drug resistance caused by BCL-2 inhibitors and provide enhanced efficacy. As a result, this trend will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global BCL-2 (B-cell lymphoma 2) inhibitors market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global BCL-2 inhibitors market is concentrated. Technavio's robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading BCL-2 inhibitors manufacturers, which include AbbVie Inc. and F. Hoffmann-La Roche Ltd.

Also, the BCL-2 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increase of patient assistance programs
  • Strategic alliances
  • Development of novel formulations

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Some of the approved combination therapies
  • Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by product
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: Prevalence, incidence, and mortality in the US are tabulated as follows.
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Key leading countries
  • Exhibit 39: Market opportunity
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: AbbVie Inc. - Vendor overview
  • Exhibit 47: AbbVie Inc. - Business segments
  • Exhibit 48: AbbVie Inc. - Organizational developments
  • Exhibit 49: AbbVie Inc. - Geographic focus
  • Exhibit 50: AbbVie Inc. - Key offerings
  • Exhibit 51: AbbVie Inc. - Key customers
  • Exhibit 52: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 53: F. Hoffmann-La Roche Ltd. - Product segments
  • Exhibit 54: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 55: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 56: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 57: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 58: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 59: Validation techniques employed for market sizing
  • Exhibit 60: Definition of market positioning of vendors
Back to Top